Troriluzole as a Treatment for Spinocerebellar Ataxia Type 3: New Drug Application by Biohaven.

Published Date: 29 Jun 2023

In a phase 3 study, a subset of spinocerebellar ataxia patients receiving troriluzole showed a numerical treatment benefit in comparison to placebo on the primary end point of change in f-SARA scores.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

2.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

3.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

4.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

5.

Telehealth in the pandemic era resulted in fewer therapy interruptions.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot